Ibio Inc (IBIO)

Apr 22, 2025, 8:00 AM EDT - 4 days ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 7, 2025, 7:00 AM EDT - 19 days ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Feb 19, 2025, 4:05 PM EST - 2 months ago

iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 10, 2025, 4:05 PM EST - 2 months ago

iBio Reports Fiscal Second Quarter 2025 Financial Results

Jan 2, 2025, 7:00 AM EST - 4 months ago

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Nov 12, 2024, 4:05 PM EST - 5 months ago

iBio Reports Fiscal First Quarter 2025 Financial Results

Sep 20, 2024, 4:05 PM EDT - 7 months ago

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sep 3, 2024, 7:00 AM EDT - 8 months ago

iBio to Participate in Upcoming Investor Conferences

Aug 12, 2024, 4:30 PM EDT - 9 months ago

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Jun 3, 2024, 7:00 AM EDT - 11 months ago

iBio Closes Sale of Manufacturing Facility in Texas

May 13, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Mar 27, 2024, 2:43 PM EDT - 1 year ago

iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 7:00 AM EDT - 1 year ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Mar 26, 2024, 7:35 PM EDT - 1 year ago

iBio Announces $15.0 Million Private Placement

Feb 26, 2024, 7:45 AM EST - 1 year ago

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Jan 16, 2024, 8:15 AM EST - 1 year ago

iBio Announces Participation in 23rd Annual PepTalk Conference

Jan 16, 2024, 6:50 AM EST - 1 year ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI VYNE

Dec 26, 2023, 7:15 AM EST - 1 year ago

iBio Amends and Extends Maturity of Credit Agreement

Dec 5, 2023, 8:00 AM EST - 1 year ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Nov 27, 2023, 5:20 PM EST - 1 year ago

iBio Announces Reverse Stock Split

Nov 1, 2023, 8:24 AM EDT - 1 year ago

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Oct 2, 2023, 6:45 AM EDT - 1 year ago

iBio Explains Recent Filing of Registration Statement

Sep 27, 2023, 4:19 PM EDT - 1 year ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 21, 2023, 4:05 PM EDT - 1 year ago

iBio Announces Amendment to Credit Agreement with Woodforest

Aug 14, 2023, 4:15 PM EDT - 1 year ago

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Jun 27, 2023, 8:00 AM EDT - 1 year ago

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

Jun 12, 2023, 4:15 PM EDT - 2 years ago

iBio Forges Research Collaboration with the National Institutes of Health

May 9, 2023, 4:30 PM EDT - 2 years ago

iBio to Participate in the JMP Securities Life Sciences Conference

Apr 4, 2023, 4:05 PM EDT - 2 years ago

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

Mar 31, 2023, 8:10 AM EDT - 2 years ago

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

Feb 16, 2023, 4:48 PM EST - 2 years ago

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

Dec 9, 2022, 4:05 PM EST - 2 years ago

iBio Announces Closing of $3.5 Million Underwritten Public Offering

Dec 6, 2022, 11:27 PM EST - 2 years ago

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

Dec 6, 2022, 4:01 PM EST - 2 years ago

iBio Announces Proposed Underwritten Public Offering

Dec 5, 2022, 8:00 AM EST - 2 years ago

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

Dec 2, 2022, 4:30 PM EST - 2 years ago

iBio Announces CEO Departure

Sep 27, 2022, 10:33 PM EDT - 2 years ago

iBio, Inc. (IBIO) Q4 2022 Results - Earnings Call Transcript

Sep 27, 2022, 4:10 PM EDT - 2 years ago

iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

Sep 21, 2022, 8:30 AM EDT - 2 years ago

iBio Acquires RubrYc Therapeutics' AI Drug Discovery Platform and Pipeline

May 12, 2022, 9:19 PM EDT - 3 years ago

iBio, Inc. (IBIO) CEO Tom Isett on Q3 2022 Results - Earnings Call Transcript

May 12, 2022, 4:05 PM EDT - 3 years ago

iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update

May 5, 2022, 4:30 PM EDT - 3 years ago

iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022

Mar 11, 2022, 8:00 AM EST - 3 years ago

iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Feb 14, 2022, 10:40 PM EST - 3 years ago

iBio, Inc. (IBIO) CEO Tom Isett on Q2 2022 Results - Earnings Call Transcript

Feb 14, 2022, 4:05 PM EST - 3 years ago

iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update

Feb 7, 2022, 4:30 PM EST - 3 years ago

iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022

Jan 26, 2022, 11:21 AM EST - 3 years ago

iBio Advances Its Vaccine Program for Multi-Variant COVID-19 Disease

Jan 4, 2022, 4:30 PM EST - 3 years ago

iBio Announces Participation in the H.C. Wainwright BioConnect Conference

Dec 22, 2021, 9:25 AM EST - 3 years ago

iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022

Dec 21, 2021, 9:20 AM EST - 3 years ago

iBio Provides Information for Listening to the Virtual Annual Stockholder Meeting